White Paper: The Benefits of Using NanoAct (Cellulose Nanobeads) in a Model Triplex Respiratory (Influenza A, Influenza B, SARS-CoV-2) Lateral Flow Assay, and Comparison to a Colloidal Gold-Based Assay

Lateral flow assays (LFAs) are widely used diagnostic tools due to their simplicity, cost-effectiveness, and rapid results. Traditionally, colloidal gold has been the most common label in these assays, valued for its ease of preparation and visible color changes. However, recent advancements in nanotechnology have introduced NanoAct™ (cellulose nanobeads) as a promising alternative, offering enhanced sensitivity, and reduced antibody usage. This white paper discusses the technical and practical advantages of NanoAct™ (cellulose nanobeads) compared to colloidal gold in lateral flow assays. Specifically, it will discuss:
 

• A comprehensive performance evaluation.
• Enhanced sensitivity and detection limits with NanoAct™.
• Comparative benefits in antibody consumption.